甲磺酸阿帕替尼联合常规化疗治疗卵巢癌疗效观察

Efficacy of Apatinib Mesylate Combined with Conventional Chemotherapy in the Treatment of Ovarian Cancer

目的 探讨甲磺酸阿帕替尼联合常规化学治疗(简称化疗)治疗卵巢癌的临床疗效,以及对患者术后血清肿瘤标志物、卵巢血流参数的影响。方法 选取医院2018年8月至2020年8月收治的卵巢癌术后患者120例,随机分为观察组和对照组,各60例。对照组患者应用紫杉醇+顺铂化疗药物联合治疗,观察组患者在对照组治疗基础上加用甲磺酸阿帕替尼片,均连续治疗3个月。结果 观察组患者的临床疗效为90.00%,显著高于对照组的68.33%(P <0.05)。治疗后,观察组患者的血清癌胚抗原(CEA)、糖蛋白抗原125(CA125)、糖蛋白抗原199(CA199)、人附睾蛋白4(HE4)水平均显著低于对照组(P <0.05);卵巢血流参数搏动指数(PI)、阻力指数(RI)均显著高于对照组,收缩期峰值流速(PSV)显著慢于对照组(P <0.05);世界卫生组织生存质量简表(WHOQOL-BREF)各维度评分均显著高于对照组(P <0.05);不良反应发生率显著低于对照组(15.00%比33.33%,P <0.05)。结论 甲磺酸阿帕替尼联合常规化疗治疗卵巢癌疗效较好,可降低患者术后的血清肿瘤标志物水平,改善卵巢血流参数,提高生活质量,且安全性良好。

Objective To investigate the clinical efficacy of apatinib mesylate combined with conventional chemotherapy in the treatment of ovarian cancer,and its effect on the serum tumor markers and ovarian blood flow parameters of patients underwent the surgery.Methods A total of 120 patients underwent the ovarian cancer surgery admitted to the hospital from August 2018 to August 2020 were selected and randomly divided into the observation group and the control group,with 60 cases in each group.The patients in the control group were treated with paclitaxel + cisplatin,on this basis,the patients in the observation group were treated with Apatinib Mesylate Tablets. Both groups were treated continuously for three months.Results The clinical efficacy in the observation group was 90. 00%,which was significantly higher than 68. 33% in the control group(P < 0. 05). After treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199) and human epididymal protein 4(HE4) in the observation group were significantly lower than those in the control group(P < 0. 05).The ovarian blood flow parameters such as pulsatility index(PI) and resistance index(RI) in the observation group were significantly higher than those in the control group,while the peak systolic velocity(PSV) in the observation group was significantly slower than that in the control group(P < 0. 05). The scores of all dimensions in the World Health Organization Quality of Life(WHOQOL)-BREF in the observation group were significantly higher than those in the control group(P < 0. 05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(15. 00% vs.33. 33%,P < 0. 05).Conclusion Apatinib mesylate combined with conventional chemotherapy is effective and safe in the treatment of ovarian cancer,which can decrease the serum tumor marker levels,improve the ovarian blood flow parameters and the quality of life of patients underwent the surgery.